Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Immune Checkpoint Inhibitors in Metastatic Melanoma: Dose Limiting Toxicity and Abscopal Effect

NCT02406183 is registered in ClinicalTrials.gov with Radiotherapie as lead sponsor.

NCT NCT02406183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02406183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Immune Checkpoint Inhibitors in Metastatic Melanoma: Dose Limiting Toxicity and Abscopal Effect
Lead sponsor
Radiotherapie
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
August 31, 2016
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse effect of radiation therapy, effects of immunotherapy, melanoma